-
公开(公告)号：EP2740744B1
公开(公告)日：2018-03-28
申请号：EP14154372.8
申请日：2008-01-09
申请人： Biogen MA Inc.
发明人： Mi, Sha , Pepinsky, R. Blake , Shao, Zhaohui , Garber Stark, Ellen A. , Miklasz, Steven D. , Graff, Christilyn
IPC分类号： C07K16/28 , A61K39/395 , A61P25/00 , A61K31/70 , A61K38/16 , C07K14/00 , C07K16/00 , C07H21/00 , C12N15/13 , C12N5/20 , C12N15/113
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such as anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present disclosure provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The disclosure further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The disclosure further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
-
公开(公告)号：EP3268042A1
公开(公告)日：2018-01-17
申请号：EP16765521.6
申请日：2016-03-11
IPC分类号： A61K39/395 , A61K38/17 , C07K14/705 , C07K16/00
CPC分类号： C07K14/7151 , A61K38/00 , A61K38/1793 , A61K2039/505 , A61K2039/545 , C07K14/525 , C07K16/241 , C07K2317/21 , C07K2319/30 , C07K2319/70
摘要： The invention provides a composition comprising an anti-tumor necrosis factor (TNF)-alpha polypeptide, wherein the composition produces a reduced level of immunogenicity when administered to a subject, as well as a treatment method involving the administration of the composition.
-
公开(公告)号：EP3265148A1
公开(公告)日：2018-01-10
申请号：EP16714601.8
申请日：2016-02-25
申请人： Biogen MA Inc.
发明人： YU, Ning , PATEL, Atul, M. , SOKHANVAR, Saeed , BRUEHWILER, Michel , CONSTANTINEAU, Cole , RAMEZANIFARD, Mohammadreza , YASEVAC, Daniel
CPC分类号： G06F19/3462 , A61M5/178 , A61M5/31 , A61M5/31511 , A61M5/31568 , A61M2005/3125 , A61M2005/3126 , A61M2205/3306 , A61M2205/332 , A61M2205/3331 , A61M2205/3368 , A61M2205/3592 , A61M2205/50 , A61M2205/581 , A61M2205/582 , A61M2205/583 , A61M2205/6063 , G06F19/00 , G06F19/3468 , G16H15/00
摘要： Embodiments of the disclosure include a transponder for determining a characteristic of a dose delivery device. The transponder may include a first sensor configured to detect a first parameter of the dose delivery device based on movement of at least one of the dose delivery device or a medicament contained within the dose delivery device, wherein the first sensor is configured to generate a first signal indicative of the first parameter. The transponder may include a processor operably coupled to the first sensor and configured to process the first signal. The transponder may include an indicator unit operably coupled to the processor and configured to generate an output based on the first signal, wherein the output is perceivable by a user. The transponder may also include a battery configured to provide power to at least one of the first sensor, the processor, and the indicator unit.
-
公开(公告)号：EP3247400A1
公开(公告)日：2017-11-29
申请号：EP16703401.6
申请日：2016-01-18
申请人： Biogen MA Inc.
发明人： KREBS, Mark , DIMITROVA, Mariana , GUPTA, Kapil , SULE, Shantanu , MAULDIN, Randy , ZUNIC, Adnan , KARPES, Lori
CPC分类号： A61K47/12 , A61K47/183 , A61K47/26 , C07K1/00 , G01N33/6803 , G01N2500/00 , G01N2500/04
摘要： Provided herein, in some aspects, are methods of developing a biological therapeutic product. The methods can be used to formulate a biological therapeutic agent or screen biological therapeutic agents.
-
公开(公告)号：EP2655624B1
公开(公告)日：2017-11-29
申请号：EP11820905.5
申请日：2011-12-22
申请人： Biogen MA Inc.
发明人： MILLER, Brian, Robert , GLASER, Scott , CARAVELLA, Justin , FOLEY, Susan , HRONOWSKI, Xiaoping , AIVAZIAN, Tigran, Dikran
CPC分类号： C07K7/08 , C07K16/241 , C07K16/2875 , C07K16/468 , C07K2317/31 , C07K2317/51 , C07K2317/622 , C07K2317/64 , C07K2317/94 , C07K2319/00 , C12N15/62
-
公开(公告)号：EP3110976A4
公开(公告)日：2017-11-22
申请号：EP15754919
申请日：2015-02-27
申请人： BIOGEN MA INC
发明人： PLAVINA TATIANA , CARULLI JOHN , GORELIK LEONID , COMPTON TERESA
CPC分类号： G01N33/6896 , C12Q1/6883 , C12Q2600/118 , C12Q2600/158 , G01N2333/025 , G01N2800/28 , G01N2800/50
摘要： The invention relates to methods of assessing a patient's risk of developing Progressive Multifocal Leukoencephalopathy (PML).
-
公开(公告)号：EP3220898A1
公开(公告)日：2017-09-27
申请号：EP15801649.3
申请日：2015-11-19
申请人： Biogen MA Inc.
发明人： KARKI, Shyam B. , ZAWANEH, Peter , LEUNG, Cheuk-Yui , VASUDEVAN, Kalyan , LIN, Yiqing , XU, Jin , TREMENTOZZI, Andrea
CPC分类号： A61K31/225 , A61K9/1676 , A61K9/209 , A61K9/2826 , A61K9/2846 , A61K9/2853 , A61K9/2866 , A61K9/2873 , A61K9/288 , A61K9/2886 , A61K9/5078 , A61P25/00 , A61P37/00
摘要： The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a bead and comprise (i) an inert core; (ii) a first layer surrounding the inert core, wherein the first layer comprises dimethyl fumarate; and (iii) an enteric coating surrounding the first layer. Also provided are pharmaceutical compositions in the form of a bead comprising a core and an enteric coating surrounding the core, wherein the core comprises dimethyl fumarate. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.
摘要翻译： 本发明提供了富马酸二甲酯的新型药物组合物。 本发明的药物组合物呈珠粒形式并包含（i）惰性核心; （ii）围绕惰性核的第一层，其中第一层包含富马酸二甲酯; 和（iii）围绕第一层的肠溶包衣。 还提供了珠形式的药物组合物，其包含核和围绕核的肠溶包衣，其中核包含富马酸二甲酯。 还包括使用本发明的药物组合物治疗多发性硬化症的方法。
-
公开(公告)号：EP2078039B1
公开(公告)日：2017-09-13
申请号：EP07873466.2
申请日：2007-11-01
申请人： Biogen MA Inc.
CPC分类号： C07K16/065 , C07K1/34
-
公开(公告)号：EP3209658A1
公开(公告)日：2017-08-30
申请号：EP15790410.3
申请日：2015-10-23
申请人： Biogen MA Inc.
发明人： CHAO, Jianhua , LUCAS, Brian
IPC分类号： C07D407/06 , C07D411/06 , C07D413/06 , C07D307/58 , A61K31/341 , A61K31/39 , A61K31/423 , A61K31/36 , A61P25/28
CPC分类号： A61K31/365 , A61K31/39 , A61K31/423 , C07D307/58 , C07D307/60 , C07D407/06 , C07D411/06 , C07D413/06
摘要： Provided herein are compounds of formula (I) and compositions containing the compounds. The compounds and compositions are useful in the methods of treating, amelioration or prophylaxix of diseases associated with Nrf2/ NF-κΒ pathways. The diseases associated include, but are not limited to a fibrotic disease such as lung fibrosis, liver fibrosis, kidney fibrosis, and scleroderma, or a neurodegenerative disease, such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, and Alzheimer's disease, and sickle cell disease.
摘要翻译： 本文提供了式（I）的化合物和含有该化合物的组合物。 所述化合物和组合物可用于治疗，改善或预防与Nrf2 / NF-κB途径相关的疾病的方法。 相关的疾病包括但不限于纤维化疾病如肺纤维化，肝纤维化，肾纤维化和硬皮病，或神经退行性疾病如多发性硬化症，肌萎缩性侧索硬化症，帕金森病，亨廷顿舞蹈病和阿尔茨海默氏病 和镰状细胞病。
-
公开(公告)号：EP3173426A1
公开(公告)日：2017-05-31
申请号：EP16195336.9
申请日：2003-02-25
申请人： Biogen MA Inc.
发明人： Taylor, Julie , Yednock, Ted A.
IPC分类号： C07K16/28 , A61K39/395 , G01N33/533 , G01N33/53 , A61P1/04 , A61P37/02 , A61P25/02
CPC分类号： C07K16/2839 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/2842 , C07K2317/24 , C07K2317/76 , G01N33/56966 , G01N2333/4737 , G01N2333/7055
摘要： A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.
摘要翻译： 公开了通过施用特异性结合α-4整联蛋白或包含α-4整联蛋白的二聚体的试剂来长期减少患者的病理性炎症的方法。 提供的试剂必须具有结合亲和力，以便施用足以抑制病理性炎症，并且该试剂长期施用以提供对病理性炎症的长期抑制。
-
-
-
-
-
-
-
-
-
搜索结果
364 条记录 (耗时 0.04 秒)
